Lab Work for Digestive System/ GI: 24.2% of denials overturned
In 149 California IMR decisions from 2006 to 2025, reviewers overturned 36 (24.2%). In the last five years: 36.8% of 19. 15 were medical-necessity disputes, 133 experimental/investigational, 1 urgent care.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 4 | 25.0% |
| 2022 | 1 | 0.0% |
| 2023 | 5 | 60.0% |
| 2024 | 5 | 60.0% |
| 2025 | 4 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 55 | 14.5% | 24.2% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 20 | 25.0% | 24.2% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 9 | 11.1% | 24.2% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 6 | 50.0% | 24.2% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for a fecal immunochemical test (FIT), urea/hydrogen breath test, and/or intravenous (IV) iron infusions. The requested FIT is not supported as medically necessary. The patient has reportedly experienced rectal bleeding, which is suggestive of lower gastrointestinal bleeding. The current guidelines for the evaluation of overt lower gastrointestinal bleeding …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for infliximab therapeutic drug assay. Based on the recommendations in the current peer-reviewed medical literature, the testing of infliximab (Remicade) levels in response to suboptimal response to therapy is considered the standard of care. Specifically, patients may be found to have low levels of infliximab …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for lab work. In this case, the patient’s infliximab levels were checked after the patient had symptoms of uncontrolled Crohn’s disease. Although not recommended for routine disease monitoring, the testing at issue is recommended by current medical guidelines for patients with ongoing disease symptoms or …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for a fecal laboratory test. The fecal laboratory test provided measures and differentiates the fecal fat to assist the provider in determining the origin of the steatorrhea. The test defines the quantity and composition of fecal fats as neutral fat or nonessential fat. In this case, the fecal fat testing …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Lab Work denials for Digestive System/ GI overturned?
In 149 California IMR decisions from 2006 to 2025, reviewers overturned 36 (24.2%). In the last five years: 36.8% of 19. 15 were medical-necessity disputes, 133 experimental/investigational, 1 urgent care.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.